上臂动静脉移植物在血液透析通路中优于前臂移植物
基于血管质量倡议(VQI)2010–2018年前瞻性收集的真实世界数据,纳入1160例前臂和509例上臂肱动脉动静脉移植物(AVG)患者,比较12个月通畅率及6个月并发症。上臂AVG的12个月一期和二期通畅率均显著高于前臂AVG,伤口感染、窃血综合征和手臂肿胀无差异。
要点
- 上臂肱动脉AVG的12个月一期和二期通畅率均显著优于前臂AVG
- 前臂AVG的一期和二期通畅丧失风险在多变量分析中显著升高
- 6个月伤口感染、窃血综合征和手臂肿胀在两组间无显著差异
核心结论
- 在上臂肱动脉AVG与前臂AVG的比较中,上臂AVG的一期和二期通畅率更优。
研究设计与样本
- 基于血管质量倡议(VQI)数据集(2010–2018)的观察性研究。
- 共识别2063例上肢AVG患者,排除腋动脉至腋动脉上臂AVG 394例后纳入分析。
- 研究队列包括1160例前臂AVG和509例上臂肱动脉AVG。
- 主要结局为12个月一期和二期通畅率,其他结局为6个月伤口感染、窃血综合征和手臂肿胀。
- 采用Kaplan-Meier分析和对数秩检验评估通畅丧失,Cox比例风险模型评估校正关联。
主要发现
- 前臂AVG患者更常见BMI>30(45% vs 38%,P=0.013)。
- 前臂AVG患者更常见无既往通路史(73% vs 63%,P<0.001)。
- 前臂AVG患者更常接受局部区域麻醉(56% vs 43%,P<0.001)。
- 前臂AVG的12个月一期通畅率显著低于上臂AVG(51.5% vs 62.9%,P<0.001)。
- 前臂AVG的12个月二期通畅率显著低于上臂AVG(76.4% vs 89.1%,P<0.001)。
关键数值与推荐
- 前臂AVG 12个月一期通畅丧失校正风险比(aHR)1.66,95%CI 1.33–2.01,P<0.001。
- 前臂AVG 12个月二期通畅丧失校正风险比(aHR)2.71,95%CI 1.84–3.98,P<0.001。
- 6个月伤口感染、窃血综合征和手臂肿胀在前臂AVG与上臂AVG之间相似。
临床怎么用
- 在制定上肢透析通路计划时,可考虑上臂肱动脉AVG在12个月通畅率方面的优势。
- 前臂AVG与上臂AVG在6个月伤口感染、窃血综合征和手臂肿胀方面表现相似。
- 选择前臂或上臂AVG位置时需综合患者特征与通畅率获益进行个体化决策。
局限性
- 本研究为基于VQI数据集的观察性研究,可能存在混杂和选择偏倚。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this study, we compared the outcomes of forearm arteriovenous grafts (AVGs) and upper arm AVGs in a large, prospectively collected data set, which represents real-world experience with upper extremity prosthetic dialysis access, to determine if there are clinically significant differences in the upper arm and forearm positions. METHODS: We identified 2,063 patients who received upper extremity AVGs within the Vascular Quality Initiative data set (2010-2018). Axillary to axillary upper arm AVGs were excluded (n = 394) from the analysis. The main outcome measures were primary and secondary patency rates at 12 months. Other outcomes were 6-month wound infection, steal syndrome, and arm swelling. The log-rank test was used to evaluate patency loss using a Kaplan-Meier analysis. Cox proportional hazards models were used to examine adjusted association between locations (forearm and upper arm) and outcomes. RESULTS: There were 1,160 forearm AVGs and 509 upper arm brachial artery AVGs in the study cohort. Patients with forearm AVGs were more likely to have a body mass index > 30 (45% vs. 38%, P = 0.013), no history of previous access (73% vs. 63%, P < 0.001), and underwent local-regional anesthesia (56% vs. 43%, P < 0.001). The 12-month primary patency (51.5% vs. 62.9%, P < 0.001) and secondary patency (76.4% vs. 89.1%, P < 0.001) were significantly lower for forearm AVGs. Wound infection, steal syndrome, and arm swelling were similar between forearm AVGs and upper arm AVGs at the 6-month follow-up. In multivariable analysis, the primary patency loss (adjusted hazard ratio (aHR) 1.66, 95% confidence interval (CI) 1.33-2.01, P < 0.001) and 12-month secondary patency loss (aHR 2.71, 95% CI 1.84-3.98, P < 0.001) were significantly higher for forearm AVGs at 12 months. CONCLUSIONS: From this observational study of the Vascular Quality Initiative data set, the primary and secondary patency rates were superior for upper arm brachial artery AVGs compared with forearm AVGs.
引用
- Fadia R, Berman SS, Chong CC, et al. Upper Arm Arteriovenous Grafts are Superior over Forearm Arteriovenous Grafts in Upper Extremity Dialysis Access. Ann Vasc Surg. 2020. PMID: 32736028. doi:10.1016/j.avsg.2020.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。